Creso Pharma makes inroads in veterinary market
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH, FRA:1X8) is pleased to announce that an estimated 100,000 dogs have benefited from the company’s anibidiol® hemp oil complementary feed range of products.
This milestone corresponds to over 3 million sachets doses of anibidiol® granules used as complementary feed.
Creso Pharma developed anibidiol® and patented its granulated delivery system.
It is produced in Switzerland and is commercialised in collaboration with Virbac S.A. (EPA:VIRP) in over 10 countries in Europe.
Global sales grew by approximately 700% in 2019.
This news comes on the back of other promising developments in the last month as management pointed to numerous share price catalysts in 2020.
With tangible developments likely to drive revenue growth in the near to medium-term it isn’t surprising that the company shares have increased by about 80% in the last month.
Today’s news is likely to provide further momentum for a company that is benefiting from its diversified business model that covers products for humans and animals, providing increasing opportunities as Creso Pharma establishes itself in multiple global markets.
Helps manage stress and pain
anibidiol® Regular and anibidiol® Plus are commercialised for small, medium-sized and large pets to support the reduction of stress and help the animals’ nervous systems to function well.
Pet owners report anibidiol® has also contributed to the management of pain and improved the vitality of their pets after one week of use in addition to normal feed.
Creso Pharma has successfully developed three additional hemp derived products to improve the wellbeing of pets which are slated for launch during 2020.
The company just launched together with Virbac Switzerland its new anibidiol® Oil 500 for pets as part of its life cycle management responding to strong demand from veterinarians and pet owners.
The product will first be marketed in Switzerland and be extended to further countries throughout the year.
Commenting on these developments and underlining the scope for distribution into new markets, Miri Halperin Wernli, Creso Pharma’s chief executive and co-founder said, “We are proud to see anibidiol® achieve this milestone, proving that pets and pet owners have an increasing appreciation of its benefits.
‘’This achievement is paving the way for launches into additional countries in other continents such as North America and Latin America, where we observe a growing need for natural complementary feed to help mitigate stress and improve the wellbeing of pets.
Creso Pharma hopes to continue leveraging the rising global trend of the ‘humanisation’ of pets, in which people treat their pets as best friends or family members.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.